http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 02 Mar 2026 07:35:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++COGNITION+THERAPEUTICS++++For%3A+Mar+02/26087057.html si-local-file:///var/storage/secattach/20260302/26087057.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++COGNITION+THERAPEUTICS++++For%3A+Mar+02/26087057.html Mon, 02 Mar 2026 07:35:00 -0500 CGTX O.04148427 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++COGNITION+THERAPEUTICS++++For%3A+Mar+02/26087057.html si-local-file:///var/storage/secattach/20260302/26087057.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++COGNITION+THERAPEUTICS++++For%3A+Mar+02/26087057.html Mon, 02 Mar 2026 07:35:00 -0500 CGTX O.04148427 http://www.streetinsider.com/Corporate+News/Cognition+Therapeutics+advances+DLB+psychosis+program+for+zervimesine/26087021.html <p>Cognition Therapeutics Inc. (NASDAQ: CGTX) announced plans to advance development of zervimesine for treating dementia with Lewy bodies psychosis, affecting up to 75% of patients with the condition. The decision follows receipt of final minutes from a U.S. Food and Drug Administration Type C meeting conducted on January 21, 2026.</p><p>The company stated it will pursue a registrational path for DLB psychosis treatment based on FDA meeting minutes and Phase 2 SHIMMER study data. No medications are currently approved for DLB psychosis, with traditional antipsychotics often contraindicated due to potential motor function impairment in these patients.</p><p>The planned study will measure neuropsychiatric http://www.streetinsider.com/Corporate+News/Cognition+Therapeutics+advances+DLB+psychosis+program+for+zervimesine/26087021.html Mon, 02 Mar 2026 07:31:53 -0500 CGTX http://www.streetinsider.com/FDA/Cognition+Therapeutics+advances+DLB+psychosis+program+for+zervimesine/26087021.html <p>Cognition Therapeutics Inc. (NASDAQ: CGTX) announced plans to advance development of zervimesine for treating dementia with Lewy bodies psychosis, affecting up to 75% of patients with the condition. The decision follows receipt of final minutes from a U.S. Food and Drug Administration Type C meeting conducted on January 21, 2026.</p><p>The company stated it will pursue a registrational path for DLB psychosis treatment based on FDA meeting minutes and Phase 2 SHIMMER study data. No medications are currently approved for DLB psychosis, with traditional antipsychotics often contraindicated due to potential motor function impairment in these patients.</p><p>The planned study will measure neuropsychiatric http://www.streetinsider.com/FDA/Cognition+Therapeutics+advances+DLB+psychosis+program+for+zervimesine/26087021.html Mon, 02 Mar 2026 07:31:53 -0500 CGTX http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html <p>PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=80qWDLnvLohQbkmTlOovC_Jf0r1y4ZvQVY2La9RURrVOzbD1M0V4d9JsPpasVRz62u4KvWpfG-J-Z-wGeEX8bvaescEZr4IYz5BwewJ8YUmgx-XLdapBDxC5ON6USukb" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.</p> <p>“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Advancing+Zervimesine+%28CT1812%29+for+Dementia+with+Lewy+Bodies+%28DLB%29+Psychosis/26086979.html Mon, 02 Mar 2026 07:30:00 -0500 A.06822034 A.19655944 A.50216367 CGTX O.03307993 O.04148427 O.20026344 O.25983652 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COGNITION+THERAPEUTICS++++For%3A+Feb+15++Filed+by%3A+Ricciardi+Lisa/26022146.html si-local-file:///var/storage/secattach/20260218/26022146.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COGNITION+THERAPEUTICS++++For%3A+Feb+15++Filed+by%3A+Ricciardi+Lisa/26022146.html Wed, 18 Feb 2026 16:17:00 -0500 CGTX O.04148427 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COGNITION+THERAPEUTICS++++For%3A+Feb+15++Filed+by%3A+Ricciardi+Lisa/26022146.html si-local-file:///var/storage/secattach/20260218/26022146.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COGNITION+THERAPEUTICS++++For%3A+Feb+15++Filed+by%3A+Ricciardi+Lisa/26022146.html Wed, 18 Feb 2026 16:17:00 -0500 CGTX O.04148427 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COGNITION+THERAPEUTICS++++For%3A+Feb+15++Filed+by%3A+Doyle+John+Brendan/26022124.html si-local-file:///var/storage/secattach/20260218/26022124.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COGNITION+THERAPEUTICS++++For%3A+Feb+15++Filed+by%3A+Doyle+John+Brendan/26022124.html Wed, 18 Feb 2026 16:16:00 -0500 CGTX O.04148427 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COGNITION+THERAPEUTICS++++For%3A+Feb+15++Filed+by%3A+Doyle+John+Brendan/26022124.html si-local-file:///var/storage/secattach/20260218/26022124.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COGNITION+THERAPEUTICS++++For%3A+Feb+15++Filed+by%3A+Doyle+John+Brendan/26022124.html Wed, 18 Feb 2026 16:16:00 -0500 CGTX O.04148427 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COGNITION+THERAPEUTICS++++For%3A+Feb+15++Filed+by%3A+Caggiano+Anthony/26022073.html si-local-file:///var/storage/secattach/20260218/26022073.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++COGNITION+THERAPEUTICS++++For%3A+Feb+15++Filed+by%3A+Caggiano+Anthony/26022073.html Wed, 18 Feb 2026 16:15:00 -0500 CGTX O.04148427